Fate Therapeutics stock stands 97.96 percent higher year to date

Published on 10/15/2026 at 18:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 2.08 million. Fate Therapeutics stock costs EUR 1.71 on October 15, 2026, down 1.10 percent on Nasdaq.

Business and valuation

Fate Therapeutics stood 97.96 percent higher year to date as of October 14, 2026.
Second-quarter revenue reached USD 2.08 million on August 13, 2026.
Fate Therapeutics stock costs EUR 1.71 at Lang & Schwarz on October 15, 2026 at 6:35 p.m. CEST, down 1.10 percent on Nasdaq on the day.
Fate Therapeutics had a market capitalization of USD 223.6 million on October 15, 2026.

FATE, US31189P1021, Illustration mit AI erstellt.

Fate Therapeutics stock stood 97.96 percent higher year to date as of October 14, 2026, compared with a 12.76 percent gain for the S&P 500. The latest market picture combines that strong annual performance with a 1.10 percent decline on Nasdaq on October 15, 2026. The stock was trading at EUR 1.71 at Lang & Schwarz on October 15, 2026 at 6:35 p.m. CEST.

Revenue reached USD 2.08 million

The company reported USD 2.08 million in revenue for the second quarter of 2026, compared with USD 1.94 million in analyst expectations. According to MarketBeat, adjusted earnings per share came to minus USD 0.25 against a consensus estimate of minus USD 0.25 on August 13, 2026. The quarterly revenue beat was USD 0.14 million, or 7.22 percent.

Price position remains wide

Fate Therapeutics traded within a 52-week range of USD 0.95 to USD 3.23 as of October 15, 2026. The latest USD 1.92 Nasdaq quote stood 40.56 percent below the yearly high and 101.05 percent above the yearly low. Trading volume reached 529,242 shares against an average of 1,667,767 shares on October 15, 2026.

Valuation and upcoming results

Fate Therapeutics had a market capitalization of USD 223.6 million and a negative price-to-earnings ratio of 1.82 on October 15, 2026. The company is a clinical-stage biotechnology business developing programmed cellular immunotherapies for cancer and immune disorders. Its reported second-quarter net loss was USD 30.2 million, while operating cash flow was negative USD 23.4 million for the period ended June 30, 2026.

Comparison with peers

Fate Therapeutics (Nasdaq, USD): minus 1.10 percent, P/E minus 1.82, market capitalization USD 223.6 million
Editas Medicine (Nasdaq, USD): plus 4.63 percent, P/E minus 3.18, market capitalization USD 364.8 million
Intellia Therapeutics (Nasdaq, USD): plus 1.53 percent, P/E minus 3.45, market capitalization USD 1.6 billion

Fate Therapeutics stock and the next data point

The contrast between the annual gain and the latest daily decline leaves the stock well inside its yearly range. The second-quarter revenue beat provides a quantified operating comparison, while the USD 30.2 million loss shows the continuing scale of cash consumption.

The Nasdaq quote was USD 1.92 on October 15, 2026 at 12:42 p.m. ET, while the euro price was trading at EUR 1.71 at Lang & Schwarz on October 15, 2026 at 6:35 p.m. CEST, down 1.10 percent on the day on Nasdaq. The further course of trading is shown by the continuously updated real-time quote of Fate Therapeutics stock.